Publicationsback

Prospective, Randomized, Double Blind, Vechicle Controlled, Multinational, Phase 3 Clinical Trial of the Pore Forming Protein PRX302 for the Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia (Plus-1 | PRX302-3-01 | BPH)

Article published on May 7, 2016
Claus Roehrborn, et al.

AUA Late-Breaking Abstract 16-8385
View JPG »